Search research articles
Contact Us
Filters
Showing results (81-90 of 147) with videos related to
Page
of 15
Sort By:
Cancer
|
September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker, Fernando O Recio, Ling Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
Jill M Spoerke, Carol O'Brien, Ling Huw, et al.
The Oncologist
|
March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing
Liangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Nature Communications
|
February 22, 2017
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau, Jeanne Cheung, Armando Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
Robert Piskol, Ling Huw, Ismail Sergin, et al.
The Journal of Pathology
|
March 25, 2024
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, et al.
Molecular Cancer Therapeutics
|
September 25, 2014
An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models
Suzie J Scales, Nidhi Gupta, Glenn Pacheco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
European Urology
|
April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma
Wenxin Xu, Brian I Rini, Laurence Albiges, et al.
Page
of 15
Search research articles
Search
Showing results (81-90 of 147) with videos related to
Sort By:
Page
of 15
Cancer
|
September 8, 2016
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker, Fernando O Recio, Ling Ma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 9, 2012
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models
Jill M Spoerke, Carol O'Brien, Ling Huw, et al.
The Oncologist
|
March 26, 2014
Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing
Liangxuan Zhang, Liangjing Chen, Sachin Sah, et al.
Nature Communications
|
February 22, 2017
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice
Janet Lau, Jeanne Cheung, Armando Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
Robert Piskol, Ling Huw, Ismail Sergin, et al.
The Journal of Pathology
|
March 25, 2024
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, et al.
Molecular Cancer Therapeutics
|
September 25, 2014
An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models
Suzie J Scales, Nidhi Gupta, Glenn Pacheco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic Melanoma
Yibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of the National Cancer Institute
|
March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma
Christy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
European Urology
|
April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma
Wenxin Xu, Brian I Rini, Laurence Albiges, et al.
Page
of 15